en
Scientific article
English

Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes

Published inScience Translational Medicine, vol. 9, no. 394
Publication date2017
Abstract

A potentially useful approach for drug discovery is to connect gene expression profiles of disease-affected tissues ("disease signatures") to drug signatures, but it remains to be shown whether it can be used to identify clinically relevant treatment options. We analyzed coexpression networks and genetic data to identify a disease signature for type 2 diabetes in liver tissue. By interrogating a library of 3800 drug signatures, we identified sulforaphane as a compound that may reverse the disease signature. Sulforaphane suppressed glucose production from hepatic cells by nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2) and decreased expression of key enzymes in gluconeogenesis. Moreover, sulforaphane reversed the disease signature in the livers from diabetic animals and attenuated exaggerated glucose production and glucose intolerance by a magnitude similar to that of metformin. Finally, sulforaphane, provided as concentrated broccoli sprout extract, reduced fasting blood glucose and glycated hemoglobin (HbA1c) in obese patients with dysregulated type 2 diabetes.

Citation (ISO format)
AXELSSON, Annika S et al. Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes. In: Science Translational Medicine, 2017, vol. 9, n° 394. doi: 10.1126/scitranslmed.aah4477
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1946-6234
412views
0downloads

Technical informations

Creation08/14/2017 3:39:00 PM
First validation08/14/2017 3:39:00 PM
Update time03/15/2023 2:22:32 AM
Status update03/15/2023 2:22:32 AM
Last indexation01/17/2024 1:24:03 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack